Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC585 in Idiopathic Pulmonary Fibrosis (IPF)
NCT07082842Phase 3Recruiting
- Sponsor
- Sunshine Lake Pharma
- Start
- Oct 2025
- Primary completion
- Jan 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of yifenidone in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Forced Vital Capacity at 52 weeks. Started Oct 2025; status: recruiting.
02
Drugs
yifenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07082842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07082842.